DHEA and Its Analog Suppress Breast Cancer Progression
Author Information
Author(s): Anne Shilkaitis, Albert Green, Vasu Punj, Vernon Steele, Ronald Lubet, Konstantin Christov
Primary Institution: University of Illinois
Hypothesis
Can dehydroepiandrosterone (DHEA) and its analog DHEA 8354 suppress the progression of premalignant lesions in the mammary gland towards malignant tumors?
Conclusion
DHEA and DHEA 8354 can suppress mammary carcinogenesis by inducing cellular senescence and inhibiting cell proliferation.
Supporting Evidence
- DHEA and DHEA 8354 decreased tumor multiplicity from 4 tumors per animal in the control group to 2.3 in the high-dose DHEA group.
- DHEA treatment increased apoptotic cells from 0.7% in control tumors to 3.2% in treated tumors.
- DHEA induced a senescent phenotype in tumor cells, increasing SA-β-Gal-stained cells significantly.
Takeaway
DHEA is like a superhero for rats' breasts, helping to stop bad cells from turning into tumors.
Methodology
Rats were treated with a carcinogen and then given DHEA or DHEA 8354 in their diet to observe effects on tumor development.
Potential Biases
Potential bias in the selection of treatment doses and the timing of administration.
Limitations
The study was conducted on rats, which may not fully represent human responses.
Participant Demographics
Female, virgin Sprague-Dawley rats.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website